Avidimab is the key19 Dec 2020 22:10
Some reminders we were expecting a deal around our mabs in September which never happened ongoing talks, then October 2nd deal with Cobra to produce our vaccine then wham 12th of October we need more funds when we havn't spent a penny of the last fund raise with the reason we need the funds to proof up our mabs
Its my opinion we pulled the rug from any mabs deal Scancell realised covidity with avidimab was going to be a game changer.
The recent rns mentions they were onto SN14 when they rns the cobra deal 2nd of October
2nd Oct 2020 7:00 am RNS Collaboration to manufacture COVID-19 vaccine
12th Oct 2020 7:00 am RNS Proposed investment by Redmile and Open Offer
17th Nov 2020 https://www.scancell.co.uk/Data/Sites/1/media/docspres/scancell-agm-2020_final.pdf
Listen to Lindy from 21.40 were she mentions adding the avidimab platform to the vaccine which gives a much better T cell response.
Then from 29.09 were Lindy talks about vaccine needs to stimulate T cells then does the thought provoking quote T cells are her reason for living that is some statement! Then goes on to talk about the t cell being important for killing viral infections as well as cancer cells then goes onto look at not just for covid 19 but future covids.
Excerpt from Fridays rns
SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:
· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.
· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.
· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.
· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using relatively simple processes.
As reported in October 2020, Scancell entered into a collaboration with Cobra Biologics, part of the Cognate BioServices family, to conduct preliminary work leading to the manufacture of SN14 with the goal of starting a Phase 1 COVIDITY clinical trial as soon as possible during 2021. The project is funded by an Innovate UK grant awarded to a consortium between Scancell, the University of Nottingham and Trent University.
Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:
"We are very excited about our SN14 second generation COVID-19 vaccine which could have significant advantages over first generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long term protection.
My opinion only, thoughts
Sign In
Follow the stocks
